KENNESAW, Ga., Feb. 11, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of four new issued patents related to tissue grafts derived from the placenta. The U.S. Patent Office has issued to MiMedx U.S. Patent Number 8,357,403, "Placental Tissue Grafts," with a grant date of January 22, 2013. The U.S Patent Office has also issued to MiMedx the following three patents with a grant date of February 12, 2013: U.S. Patent Number 8,372,437, "Improved Placental Tissue Grafts"; U.S. Patent Number 8,372,438, "Method For Inhibiting Adhesion Formation Using Improved Placental Grafts"; and U.S. Patent Number 8,372,439, "Method For Treating a Wound Using Improved Placental Tissue Graft." The new patents relate to the Company's placental tissue allografts, including AmnioFix® and EpiFix® brand allografts.
"These four newly issued patents bring the total to five placental-based U.S. patents that we have recently been issued," said Parker H. "Pete" Petit, Chairman and CEO. "We are pleased with the pace of review and acceptance of our patent applications preserving the unique intellectual property of our proprietary AmnioFix® and EpiFix® technologies. At present, we have in excess of 20 additional patent applications that have been filed with the U.S. Patent Office relating to these technologies and our placental tissue allografts. We are encouraged about the prospects of receiving more significant patent issuances resulting from our filings."
Bill Taylor , President and COO, commented, "These newly issued patents represent only a portion of the unique aspects of our PURION® process for amniotic tissues and the resulting allografts. Our special processing and cleansing of the amniot
|SOURCE MiMedx Group, Inc.|
Copyright©2012 PR Newswire.
All rights reserved